MedPath

Orient Pharma Co., Ltd.

Orient Pharma Co., Ltd. logo
🇹🇼Taiwan
Ownership
Public
Established
2008-01-01
Employees
-
Market Cap
-
Website
http://www.oppharma.com

Clinical Trials

6

Active:0
Completed:6

Trial Phases

2 Phases

Phase 2:2
Phase 3:4

Drug Approvals

4

FDA:4

Drug Approvals

Ezetimibe

Approval Date
Nov 13, 2023
FDA

Miglitol

Approval Date
Oct 23, 2019
FDA

Glyburide

Approval Date
Feb 26, 2019
FDA

Carisoprodol

Approval Date
Feb 12, 2019
FDA

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 3
4 (66.7%)
Phase 2
2 (33.3%)

Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Phase 3
Completed
Conditions
Primary Hypercholesterolemia
Mixed Dyslipidemias
Interventions
First Posted Date
2020-11-24
Last Posted Date
2022-05-18
Lead Sponsor
Orient Pharma Co., Ltd.
Target Recruit Count
390
Registration Number
NCT04643093
Locations
🇦🇺

Paratus Clinical Research Western Sydney, Blacktown, Australia

🇦🇺

Northern Beaches Clinical Research, Brookvale, Australia

🇦🇺

Emeritus Research, Camberwell, Australia

and more 31 locations

Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD

Phase 3
Completed
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Drug: ORADUR®-Methylphenidate
First Posted Date
2016-03-10
Last Posted Date
2021-12-15
Lead Sponsor
Orient Pharma Co., Ltd.
Target Recruit Count
64
Registration Number
NCT02704390
Locations
🇨🇳

Chang Gung Medical Foundation- Chiayi Branch, Chiayi City, Taiwan

🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

🇨🇳

Chang Gung Medical Foundation- Linkuo Branch, Taoyuan, Taiwan

Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis

Phase 2
Completed
Conditions
Pulmonary Tuberculosis
Interventions
First Posted Date
2015-06-10
Last Posted Date
2022-06-15
Lead Sponsor
Orient Pharma Co., Ltd.
Target Recruit Count
557
Registration Number
NCT02467608
Locations
🇨🇳

Changhua Christian Hospital, Changhua, Taiwan

🇨🇳

Changhua Hosiptal Ministry of Health And Welfare, Changhua, Taiwan

🇨🇳

Chang Gung Memorial Hospital, ChiaYi, Chiayi City, Taiwan

and more 15 locations

Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD

Phase 3
Completed
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Drug: ORADUR® First, then Placebo
Drug: Placebo First, then ORADUR®
First Posted Date
2015-05-21
Last Posted Date
2021-12-06
Lead Sponsor
Orient Pharma Co., Ltd.
Target Recruit Count
114
Registration Number
NCT02450890
Locations
🇨🇳

Chang Gung Medical Foundation- Chiayi Branch, Chiayi City, Taiwan

🇨🇳

Tri-Service General Hospital, Taipei City, Taiwan

🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

and more 1 locations

Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia

Phase 3
Completed
Conditions
Hypercholesterolemia
Interventions
Drug: 1PC002
First Posted Date
2012-10-18
Last Posted Date
2023-07-17
Lead Sponsor
Orient Pharma Co., Ltd.
Target Recruit Count
202
Registration Number
NCT01710007
Locations
🇨🇳

Buddhist Taipei TzuChi General Hospital, New Taipei City, Taiwan

🇨🇳

Cardinal Tien Hospital, New Taipei City, Taiwan

🇨🇳

Taipei Medical University - Shuang Ho Hospital, New Taipei City, Taiwan

and more 5 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.